LA| Louisiana Department of Insurance Directive 230 clarifies the reporting standard for “significant price increase” under La. R.S. 22:1870(B)(5), enacted by Act 474 of the 2025 Regular Session, which requires pharmaceutical manufacturers to report certain drug price increases within a twelve‑month period. The directive defines a significant price increase for generic or biosimilar drugs as a price rise of 40% or more within twelve months for drugs with a wholesale acquisition cost between $10 and $100, and 15% or more within twelve months for drugs priced over $100. Manufacturers must provide notice to the Commissioner within 30 days after such increases (or after specified brand‑name increases or high‑cost new drug introductions) and must include detailed information about the drug and an explanation of the reason for the increase, including whether it was related to rebates or formulary requirements.
Home » Bulletins » New Louisiana Rule: Drug Manufacturers Must Report Large Price Increases Within 30 Days Under Act 474 Standard